CACNA1E in Cancer Diagnosis, Detection and Treatment
OwnerGuoying Yu, Edward Moler +3inventors
InventorsGuoying Yu, Edward Moler, Michael Rowe, Christin Tse, Xie Xu
Life of this patent
Estimating the term…
Abstract
This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the CACNA1E gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the CACNA1E gene.
Claims38
A method for treating cancer in a patient comprising modulating the level of an expression product of CACNA1E wherein the cancer is selected from the group consisting of breast cancer, colon cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, uterine cancer and colon metastais
A method of treating a cancer in a patient characterized by overexpression of CACNA1E relative to a control, the method comprising modulating CACNA1E gene expression in the patient.
A method for diagnosing cancer comprising detecting evidence of differential expression in a patient sample of CACNA1E wherein evidence of differential expression of CACNA1E is diagnostic of cancer, wherein the cancer is selected from the group consisting of breast cancer, liver cancer, colon cancer, rectal cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, uterine cancer and colon metastais.
The method of claim 24 wherein the control is a known normal tissue of the same tissue type as in the patient sample.
A method for detecting a cancerous cell in a patient sample comprising detecting evidence of an expression product of CACNA1E, wherein evidence of expression of CACNA1E in the sample indicates that a cell in the sample is cancerous.
A method for assessing the progression of cancer in a patient comprising comparing the level of an expression product of CACNA1E in a biological sample at a first time point to a level of the same expression product at a second time point, wherein a change in the level of the expression product at the second time point relative to the first time point is indicative of the progression of the cancer, wherein the cancer is selected from the group consisting of breast cancer, liver cancer, lung cancer, colon cancer, rectal cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, uterine cancer and colon metastais.
A method of diagnosing cancer selected from the group consisting of breast cancer, liver cancer, lung cancer, ovarian cancer, colon cancer, rectal cancer, pancreatic cancer, prostate cancer, skin cancer, uterine cancer and colon metastais, the method comprising:
- (a) measuring a level of mRNA of CACNA1E in a first sample, said first sample comprising a first tissue type of a first individual;
- and
- (b) comparing the level of mRNA in (a) to:
- (1) a level of the mRNA in a second sample, said second sample comprising a normal tissue type of said first individual, or
- (2) a level of the mRNA in a third sample, said third sample comprising a normal tissue type from an unaffected individual;
- wherein at least a two fold difference between the level of mRNA in (a) and the level of the mRNA in the second sample or the third sample indicates that the first individual has or is predisposed to cancer.
A method of screening for anti-cancer activity comprising:
- (a) contacting a cell that expresses CACNA1E with a candidate anti-cancer agent;
- and
- (b) detecting at least a two fold difference between the level of CACNA1E expression in the cell in the presence and in the absence of the candidate anti-cancer agent,
- wherein at least a two fold difference between the level of CACNA1E expression in the cell in the presence and in the absence of the candidate anti-cancer agent indicates that the candidate anti-cancer agent has anti-cancer activity, wherein the cancer is selected from the group consisting of breast cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, colon cancer, rectal cancer, prostate cancer, skin cancer, uterine cancer and colon metastais.
A method for identifying a patient as susceptible to treatment with an antibody that binds to an expression product of CACNA1E comprising measuring the level of the expression product of the gene in a biological sample from that patient.
A kit for the diagnosis or detection of cancer in a mammal, wherein said kit comprises an antibody or fragment thereof, or an immunoconjugate or fragment thereof, according to any one of the proceeding embodiments, wherein said antibody or fragment specifically binds an CACNA1E tumor cell antigen;
- one or more reagents for detecting a binding reaction between said antibody and said CACNA1E tumor cell antigen;
- and optionally instructions for using the kit, wherein the cancer is selected from the group consisting of breast cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, colon cancer, rectal cancer, prostate cancer, skin cancer, uterine cancer and colon metastais.
A kit for diagnosing cancer comprising a nucleic acid probe that hybridises under stringent conditions to an CACNA1E gene;
- primers for amplifying the CACNA1E gene;
- and optionally instructions for using the kit, wherein the cancer is selected from the group consisting of breast cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, colon cancer, rectal cancer, prostate cancer, skin cancer, uterine cancer and colon metastais.
A composition comprising one or more antibodies or oligonucleotides specific for an expression product of CACNA1E.
Dependencies are inferred from the claim text.